Trial Profile
Multi-center, Single Stage Phase II Study to Evaluate the Efficacy and Safety of Flumatinib in Accelerated or Blastic Phase Chronic Myelogenous Leukemia Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Flumbatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 04 Aug 2015 New trial record